Boulder, Colorado - September 17, 2009 - Bolder BioTechnology, Inc. today announced that it has been awarded two Phase I Small Business Innovation Research (SBIR) grants totaling $1.2 million from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grants will be used to perform additional preclinical toxicology…
Read more
Bolder BioTechnology Receives $1.9 million NIH Grant to Continue Development of Long-Acting Growth Hormone Product
Boulder, Colorado - December 16, 2008 - Bolder BioTechnology, Inc. today announced that it has been awarded a $1.9 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to perform additional preclinical toxicology and…
Read more
Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
Boulder, Colorado - October 15, 2008 - Bolder BioTechnology, Inc. announced today that it has been awarded a $1.6 million Phase II Continuing Renewal Small Business Innovation Research (SBIR) grant, entitled “Long-Acting Beta Interferon for Multiple Sclerosis”, from the National Institute of Neurological Disorders and Stroke (NINDS) of The National Institutes of Health (NIH). Receipt of…
Read more
Bolder BioTechnology Awarded NIH Grant to Continue Development of Novel Arthritis Treatment
Boulder, Colorado - August 24, 2007 - Bolder BioTechnology, Inc. today announced that it has been awarded a $685,984 Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of The National Institutes of Health. The grant provides funds to continue research to optimize a human protein…
Read more